Quarterly report pursuant to Section 13 or 15(d)

Leases

v3.22.4
Leases
6 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Leases

Note 7. Leases:

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016-02 and related standards (collectively ASC 842, Leases), which replaced previous lease accounting guidance, on July 1, 2019.

The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is Bio-Techne’s incremental borrowing rate or, if available, the rate implicit in the lease. Bio-Techne determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During the six months ended December 31, 2022, the Company recognized $2.0 million in variable lease expense and $7.1 million relating to fixed lease expense in the Condensed Consolidated Statements of Earnings and Comprehensive Income.

The following table summarizes the balance sheet classification of the Company’s operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):

    

    

As of

December 31, 

Balance Sheet Classification

2022

Operating leases:

 

  

 

  

Operating lease right of use assets

 

Right of Use Asset

$

83,937

Current operating lease liabilities

 

Operating lease liabilities current

$

10,975

Noncurrent operating lease liabilities

 

Operating lease liabilities

 

78,183

Total operating lease liabilities

$

89,158

Weighted average remaining lease term (in years):

 

 

9.77

Weighted average discount rate (%):

 

 

4.23

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the six months ended December 31, 2022 (in thousands):

Six months ended

December 31, 

    

2022

Cash amounts paid on operating lease liabilities

$

7,294

Right of use assets obtained in exchange for lease liabilities

 

26,553

The following table summarizes the fair value of the lease liability by payment date for the Company’s operating leases by fiscal year (in thousands):

    

December 31, 2022

Operating

Leases

Remainder 2023

$

7,237

2024

 

13,236

2025

 

12,328

2026

 

11,211

2027

 

9,524

Thereafter

 

57,035

Total

$

110,571

Less: Amounts representing interest

 

21,413

Total Lease obligations

$

89,158

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. Bio-Techne includes the option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, Bio-Techne is not reasonably certain to exercise such options.